Nuvectis Pharma, Inc.
NASDAQ Capital MarketTotal Valuation
Nuvectis Pharma, Inc. carries a market capitalization of 649.88M, placing it among publicly traded companies globally.
| Market Cap | 649.88M |
| Enterprise Value | N/A |
Share Statistics
Nuvectis Pharma, Inc. currently has 26.69M shares outstanding.
| Shares Outstanding | 26.69M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 54.05 |
| P/TBV Ratio | 54.05 |
| P/FCF Ratio | -21.87 |
| P/OCF Ratio | -21.87 |
Financial Position
Nuvectis Pharma, Inc. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.68 |
| Quick Ratio | 1.67 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -214.58 |
| Return on Assets (ROA) | -112.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Nuvectis Pharma, Inc.'s stock has gained approximately 275.6135% over the past 52 weeks. The 50-day moving average sits at 21.06, while the 200-day moving average is 11.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | 275.6135% |
| 50-Day Moving Average | 21.06 |
| 200-Day Moving Average | 11.91 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -28.87M, while operating income came in at -28.87M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -28.87M |
| Pretax Income | -27.85M |
| Net Income | -27.85M |
| EBITDA | -28.87M |
| EBIT | -28.87M |
| Earnings Per Share (EPS) | -1.20 |
Balance Sheet
Total book value stands at 9.08M, with working capital of 9.08M providing operational flexibility.
| Cash & Cash Equivalents | 22.16M |
| Total Debt | N/A |
| Net Debt | -22.16M |
| Equity (Book Value) | 9.08M |
| Book Value Per Share | 0.34 |
| Working Capital | 9.08M |
Cash Flow
Nuvectis Pharma, Inc. produced -19.51M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.51M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.51M |
| FCF Per Share | -0.84 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.03 |
| FCF Yield | -4.57 |
Scores
Nuvectis Pharma, Inc. posts an Altman Z-Score of 11.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.33 |